✦ LIBER ✦

Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome

✍ Scribed by Michelle L. O'Donoghue; Eugene Braunwald; Harvey D. White; Patrick Serruys; Ph. Gabriel Steg; Judith Hochman; Aldo P. Maggioni; Christoph Bode; Douglas Weaver; Joel L. Johnson; Greg Cicconetti; Mary Ann Lukas; Elizabeth Tarka; Christopher P. Cannon

Book ID: 116192578
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 300 KB
Volume: 162
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2011.07.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Study design and rationale for the clini

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

✍ Harvey White; Claes Held; Ralph Stewart; David Watson; Robert Harrington; Andrze 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 341 KB

Evaluation of prasugrel compared with cl

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)

✍ Stephen D. Wiviott; Elliott M. Antman; C. Michael Gibson; Gilles Montalescot; Je 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 276 KB

Evaluation of prasugrel compared with cl

✍ Stephen D. Wiviott; Elliott M. Antman; C. Michael Gibson; Gilles Montalescot; Je 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 276 KB

Myeloid-related protein 8/14 and the ris

✍ David A. Morrow; Yunmei Wang; Kevin Croce; Masashi Sakuma; Marc S. Sabatine; Hui 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB

Assessment of adiponectin and the risk o

Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22)

✍ Sean R. Wilson; Marc S. Sabatine; Stephen D. Wiviott; Kausik K. Ray; James A. De 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 278 KB